I agree and in almost all cases in the OTC you would be right. I'm always skeptical myself until proven otherwise, but here at least from the looks of it we don't have a company that has been putting out PR after PR to just pump the stock up in order to dilute shares for the noteholder, which is often times the case. The last PR in fact was mid April, in which they mentioned getting current back then. The latest 2 PR's are starting to bring things together, and the move from California to Texas is just another piece of the puzzle that's headed in the right direction. Of course the merger could fall apart and not happen, and for whatever reason they may not get current, but like yourself my average here is .0006, so I can afford to see this one through here for awhile. Only way I see trips again is if the merger falls through, as there has been tons of money flowing through over the past couple of weeks. 4 out of the past 5 trading days had a close of .0059 or .0060, so it's showing pretty amazing strength at the moment. Market cap is what it's all about, and a $14 million one is nothing for a biotech one with this potential.
Market Data 
Markets 
AI
